;PMID: 11936570
;source_file_654.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..158] = [t:45..158]
;2)section:[e:162..188] = [t:162..188]
;3)section:[e:192..332] = [t:192..332]
;4)sentence:[e:336..522] = [t:336..522]
;5)sentence:[e:523..737] = [t:523..737]
;6)sentence:[e:738..855] = [t:738..855]
;7)sentence:[e:856..1019] = [t:856..1019]
;8)sentence:[e:1020..1135] = [t:1020..1135]
;9)sentence:[e:1136..1337] = [t:1136..1337]
;10)section:[e:1341..1359] = [t:1341..1359]
;11)section:[e:1365..1379] = [t:1365..1379]
;12)section:[e:1385..1408] = [t:1385..1408]
;13)section:[e:1414..1441] = [t:1414..1441]
;14)section:[e:1445..1490] = [t:1445..1490]

;section 0 Span:0..39
;J Clin Pharmacol. 2002 Apr;42(4):444-9.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Clin) (NNP:[7..16] Pharmacol) (.:[16..17] .)
        (CD:[18..22] 2002) (CC:[23..30] Apr;42-LRB-) (CD:[30..31] 4)
        (-RRB-:[31..32] -RRB-) (::[32..33] :) (CD:[33..36] 444) (::[36..37] -)
        (CD:[37..39] 9.)))

;sentence 1 Span:45..158
;A study of the interaction potential of azithromycin and clarithromycin with 
;atorvastatin in healthy volunteers.
;[85..97]:substance:"azithromycin"
;[102..116]:substance:"clarithromycin"
;[123..135]:substance:"atorvastatin"
(SENT
  (NP-HLN
    (NP (DT:[45..46] A) (NN:[47..52] study))
    (PP (IN:[53..55] of)
      (NP
        (NP (DT:[56..59] the) (NN:[60..71] interaction) (NN:[72..81] potential))
        (PP (IN:[82..84] of)
          (NP (NN:[85..97] azithromycin) (CC:[98..101] and)
              (NN:[102..116] clarithromycin)))
        (PP (IN:[117..121] with)
          (NP (NN:[123..135] atorvastatin)))))
    (PP-LOC (IN:[136..138] in)
      (NP (JJ:[139..146] healthy) (NNS:[147..157] volunteers)))
    (.:[157..158] .)))

;section 2 Span:162..188
;Amsden GW, Kuye O, Wei GC.
(SEC
  (FRAG (NNP:[162..168] Amsden) (NNP:[169..171] GW) (,:[171..172] ,)
        (NNP:[173..177] Kuye) (NNP:[178..179] O) (,:[179..180] ,)
        (NNP:[181..184] Wei) (NNP:[185..187] GC) (.:[187..188] .)))

;section 3 Span:192..332
;Clinical Pharmacology Research Center, Research Institute and Department of 
;Medicine, Bassett Healthcare, Cooperstown, New York 13326, USA.
(SEC
  (FRAG (NNP:[192..200] Clinical) (NNP:[201..213] Pharmacology)
        (NNP:[214..222] Research) (NNP:[223..229] Center) (,:[229..230] ,)
        (NNP:[231..239] Research) (NNP:[240..249] Institute) (CC:[250..253] and)
        (NNP:[254..264] Department) (IN:[265..267] of) (NNP:[269..277] Medicine)
        (,:[277..278] ,) (NNP:[279..286] Bassett) (NNP:[287..297] Healthcare)
        (,:[297..298] ,) (NNP:[299..310] Cooperstown) (,:[310..311] ,)
        (NNP:[312..315] New) (NNP:[316..320] York) (CD:[321..326] 13326)
        (,:[326..327] ,) (NNP:[328..331] USA) (.:[331..332] .)))

;sentence 4 Span:336..522
;Atorvastatin is a common option among the HMG-CoA reductase inhibitors for
;the  treatment of lipid disorders because of its excellent lipid-lowering
;efficacy  and overall safety profile.
;[336..348]:substance:"Atorvastatin"
;[378..395]:substance:"HMG-CoA reductase"
;[396..406]:substance:"inhibitors"
;[429..434]:substance:"lipid"
;[470..475]:substance:"lipid"
(SENT
  (S
    (NP-SBJ (NN:[336..348] Atorvastatin))
    (VP (VBZ:[349..351] is)
      (NP-PRD
        (NP (DT:[352..353] a) (JJ:[354..360] common) (NN:[361..367] option))
        (PP (IN:[368..373] among)
          (NP (DT:[374..377] the)
            (NML
              (NML (NN:[378..381] HMG) (HYPH:[381..382] -) (NN:[382..385] CoA))
              (NN:[386..395] reductase))
            (NNS:[396..406] inhibitors)))
        (PP (IN:[407..410] for)
          (NP
            (NP (DT:[411..414] the) (NN:[416..425] treatment))
            (PP (IN:[426..428] of)
              (NP (NN:[429..434] lipid) (NNS:[435..444] disorders))))))
      (PP (IN:[445..452] because)
        (PP (IN:[453..455] of)
          (NP (PRP$:[456..459] its)
            (NML
              (NML (JJ:[460..469] excellent)
                (ADJP (NN:[470..475] lipid) (HYPH:[475..476] -)
                      (VBG:[476..484] lowering))
                (NN:[485..493] efficacy))
              (CC:[495..498] and)
              (NML (JJ:[499..506] overall) (NN:[507..513] safety)
                   (NN:[514..521] profile)))))))
    (.:[521..522] .)))

;sentence 5 Span:523..737
;Although these agents can rarely cause  rhabdomyolysis by themselves,
;macrolides, among other agents, have been  demonstrated to increase the
;likelihood of this via inhibition of CYP metabolism  of the lipid agent.
;[538..544]:substance:"agents"
;[593..603]:substance:"macrolides"
;[617..623]:substance:"agents"
;[702..705]:cyp450:"CYP"
;[725..730]:substance:"lipid"
;[731..736]:substance:"agent"
(SENT
  (S
    (SBAR-ADV (IN:[523..531] Although)
      (S
        (NP-SBJ (DT:[532..537] these) (NNS:[538..544] agents))
        (VP (MD:[545..548] can)
          (ADVP (RB:[549..555] rarely))
          (VP (VB:[556..561] cause)
            (NP (NN:[563..577] rhabdomyolysis))
            (PP (IN:[578..580] by)
              (NP (PRP:[581..591] themselves)))))))
    (,:[591..592] ,)
    (NP-SBJ-1
      (NP (NNS:[593..603] macrolides))
      (,:[603..604] ,)
      (PP (IN:[605..610] among)
        (NP (JJ:[611..616] other) (NNS:[617..623] agents))))
    (,:[623..624] ,)
    (VP (VBP:[625..629] have)
      (VP (VBN:[630..634] been)
        (VP (VBN:[636..648] demonstrated)
          (S
            (NP-SBJ-1 (-NONE-:[648..648] *))
            (VP (TO:[649..651] to)
              (VP (VB:[652..660] increase)
                (NP
                  (NP (DT:[661..664] the) (NN:[665..675] likelihood))
                  (PP (IN:[676..678] of)
                    (NP (DT:[679..683] this))))
                (PP-MNR (IN:[684..687] via)
                  (NP
                    (NP (NN:[688..698] inhibition))
                    (PP (IN:[699..701] of)
                      (NP
                        (NP (NN:[702..705] CYP) (NN:[706..716] metabolism))
                        (PP (IN:[718..720] of)
                          (NP (DT:[721..724] the) (NN:[725..730] lipid)
                              (NN:[731..736] agent)))))))))))))
    (.:[736..737] .)))

;sentence 6 Span:738..855
;This study investigated the potential for azithromycin and  clarithromycin to
;inhibit the metabolism of atorvastatin.
;[780..792]:substance:"azithromycin"
;[798..812]:substance:"clarithromycin"
;[842..854]:substance:"atorvastatin"
(SENT
  (S
    (NP-SBJ (DT:[738..742] This) (NN:[743..748] study))
    (VP (VBD:[749..761] investigated)
      (NP
        (NP (DT:[762..765] the) (NN:[766..775] potential)
          (S-1 (-NONE-:[775..775] *ICH*)))
        (PP (IN:[776..779] for)
          (NP (NN:[780..792] azithromycin) (CC:[793..796] and)
              (NN:[798..812] clarithromycin)))
        (S-1
          (NP-SBJ (-NONE-:[812..812] *))
          (VP (TO:[813..815] to)
            (VP (VB:[816..823] inhibit)
              (NP
                (NP (DT:[824..827] the) (NN:[828..838] metabolism))
                (PP (IN:[839..841] of)
                  (NP (NN:[842..854] atorvastatin)))))))))
    (.:[854..855] .)))

;sentence 7 Span:856..1019
;Although there was no  interaction between azithromycin and atorvastatin,
;clarithromycin did have a  significant effect on atorvastatin pharmacokinetic
;parameters.
;[899..911]:substance:"azithromycin"
;[916..928]:substance:"atorvastatin"
;[930..944]:substance:"clarithromycin"
;[979..991]:substance:"atorvastatin"
(SENT
  (S
    (SBAR-ADV (IN:[856..864] Although)
      (S
        (NP-SBJ (EX:[865..870] there))
        (VP (VBD:[871..874] was)
          (NP-PRD
            (NP (DT:[875..877] no) (NN:[879..890] interaction))
            (PP (IN:[891..898] between)
              (NP (NN:[899..911] azithromycin) (CC:[912..915] and)
                  (NN:[916..928] atorvastatin)))))))
    (,:[928..929] ,)
    (NP-SBJ (NN:[930..944] clarithromycin))
    (VP (VBD:[945..948] did)
      (VP (VB:[949..953] have)
        (NP
          (NP (DT:[954..955] a) (JJ:[957..968] significant)
              (NN:[969..975] effect))
          (PP (IN:[976..978] on)
            (NP (NN:[979..991] atorvastatin) (JJ:[992..1007] pharmacokinetic)
                (NNS:[1008..1018] parameters))))))
    (.:[1018..1019] .)))

;sentence 8 Span:1020..1135
;When  coadministered, clarithromycin raised subject exposure (AUC24) by 82%
;and peak  plasma concentrations by 56%.
;[1042..1056]:substance:"clarithromycin"
;[1082..1087]:quantitative-name:"AUC24"
;[1092..1095]:quantitative-value:"82%"
;[1131..1134]:quantitative-value:"56%"
(SENT
  (S
    (SBAR-TMP
      (WHADVP-6 (WRB:[1020..1024] When))
      (S
        (NP-SBJ-5 (-NONE-:[1024..1024] *))
        (VP (VBN:[1026..1040] coadministered)
          (NP-5 (-NONE-:[1040..1040] *))
          (ADVP-TMP-6 (-NONE-:[1040..1040] *T*)))))
    (,:[1040..1041] ,)
    (NP-SBJ (NN:[1042..1056] clarithromycin))
    (VP
      (VP (VBD:[1057..1063] raised)
        (NP=2 (NN:[1064..1071] subject) (NN:[1072..1080] exposure)
          (PRN (-LRB-:[1081..1082] -LRB-) (NN:[1082..1087] AUC24)
               (-RRB-:[1087..1088] -RRB-)))
        (PP-EXT=3 (IN:[1089..1091] by)
          (NP (CD:[1092..1094] 82) (NN:[1094..1095] %))))
      (CC:[1096..1099] and)
      (VP
        (NP=2 (JJ:[1100..1104] peak) (NN:[1106..1112] plasma)
              (NNS:[1113..1127] concentrations))
        (PP-EXT=3 (IN:[1128..1130] by)
          (NP (CD:[1131..1133] 56) (NN:[1133..1134] %)))))
    (.:[1134..1135] .)))

;sentence 9 Span:1136..1337
;These data suggest that while azithromycin appears  to be safe to
;coadminister with atorvastatin, clarithromycin should be avoided  in patients
;taking this and similarly metabolized HMG-CoA inhibitors.
;[1166..1178]:substance:"azithromycin"
;[1220..1232]:substance:"atorvastatin"
;[1234..1248]:substance:"clarithromycin"
;[1318..1325]:substance:"HMG-CoA"
;[1326..1336]:substance:"inhibitors"
(SENT
  (S
    (NP-SBJ (DT:[1136..1141] These) (NNS:[1142..1146] data))
    (VP (VBP:[1147..1154] suggest)
      (SBAR (IN:[1155..1159] that)
        (S
          (SBAR-ADV (IN:[1160..1165] while)
            (S
              (NP-SBJ-2 (NN:[1166..1178] azithromycin))
              (VP (VBZ:[1179..1186] appears)
                (S
                  (NP-SBJ-2 (-NONE-:[1186..1186] *))
                  (VP (TO:[1188..1190] to)
                    (VP (VB:[1191..1193] be)
                      (ADJP-PRD (JJ:[1194..1198] safe)
                        (S
                          (NP-SBJ-2 (-NONE-:[1198..1198] *))
                          (VP (TO:[1199..1201] to)
                            (VP (VB:[1202..1214] coadminister)
                              (PP-CLR (IN:[1215..1219] with)
                                (NP (NN:[1220..1232] atorvastatin)))))))))))))
          (,:[1232..1233] ,)
          (NP-SBJ-1 (NN:[1234..1248] clarithromycin))
          (VP (MD:[1249..1255] should)
            (VP (VB:[1256..1258] be)
              (VP (VBN:[1259..1266] avoided)
                (NP-1 (-NONE-:[1266..1266] *))
                (PP-LOC (IN:[1268..1270] in)
                  (NP
                    (NP (NNS:[1271..1279] patients))
                    (VP (VBG:[1280..1286] taking)
                      (NP
                        (NP (DT:[1287..1291] this)
                          (NML-3 (-NONE-:[1291..1291] *P*)))
                        (CC:[1292..1295] and)
                        (NP
                          (ADJP (RB:[1296..1305] similarly)
                                (VBN:[1306..1317] metabolized))
                          (NML-3
                            (NML (NN:[1318..1321] HMG) (HYPH:[1321..1322] -)
                                 (NN:[1322..1325] CoA))
                            (NNS:[1326..1336] inhibitors)))))))))))))
    (.:[1336..1337] .)))

;section 10 Span:1341..1359
;Publication Types:
(SEC
  (NP (NNP:[1341..1352] Publication) (NNP:[1353..1358] Types) (::[1358..1359] :)))

;section 11 Span:1365..1379
;Clinical Trial
(SEC
  (NP (NNP:[1365..1373] Clinical) (NNP:[1374..1379] Trial)))

;section 12 Span:1385..1408
;Clinical Trial, Phase I
(SEC
  (NP
    (NP (NNP:[1385..1393] Clinical) (NNP:[1394..1399] Trial))
    (,:[1399..1400] ,)
    (NP (NN:[1401..1406] Phase) (PRP:[1407..1408] I))))

;section 13 Span:1414..1441
;Randomized Controlled Trial
(SEC
  (NP (NNP:[1414..1424] Randomized) (NNP:[1425..1435] Controlled)
      (NNP:[1436..1441] Trial)))

;section 14 Span:1445..1490
;PMID: 11936570 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1445..1449] PMID) (::[1449..1450] :) (CD:[1451..1459] 11936570)
        (NN:[1460..1461] -LSB-) (NNP:[1461..1467] PubMed) (::[1468..1469] -)
        (NN:[1470..1477] indexed) (IN:[1478..1481] for)
        (NNP:[1482..1490] MEDLINE-RSB-)))
